Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$160.01 USD

160.01
2,428,830

+0.32 (0.20%)

Updated Oct 9, 2024 03:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

Johnson & Johnson (JNJ) closed at $178 in the latest trading session, marking a +1.08% move from the prior day.

Horizon (HZNP) Up on Initial Talks of Buyout by Pharma Giants

Horizon (HZNP) holds preliminary discussions with Amgen, Sanofi and Janssen, a subsidiary of J&J, seeking an offer for its acquisition by any one of the pharma giants. Shares rise.

Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?

Smart Beta ETF report for HDV

Should Vanguard Value ETF (VTV) Be on Your Investing Radar?

Style Box ETF report for VTV

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Here's What's Driving AbbVie's (ABBV) Outperformance This Year

AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why

Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.

Should Schwab U.S. LargeCap Value ETF (SCHV) Be on Your Investing Radar?

Style Box ETF report for SCHV

Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?

Smart Beta ETF report for DGRW

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

Style Box ETF report for HDV

Johnson & Johnson (JNJ) Up 5.3% Since Last Earnings Report: Can It Continue?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use

The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Should Vanguard Russell 1000 Value ETF (VONV) Be on Your Investing Radar?

Style Box ETF report for VONV

Should iShares S&P 500 Value ETF (IVE) Be on Your Investing Radar?

Style Box ETF report for IVE

Should Vanguard S&P 500 Value ETF (VOOV) Be on Your Investing Radar?

Style Box ETF report for VOOV

Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?

Smart Beta ETF report for VYM

Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates

Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services

Halozyme's (HALO) Q3 Earnings and Revenues Surpass Estimates

Halozyme's (HALO) earnings and revenues beat estimates for the third quarter of 2022.

Bayer's (BAYRY) Q3 Earnings Miss Estimates, Revenues Top

Bayer's (BAYRY) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.

Theravance (TBPH) Q3 Loss Narrower Than Expected, Sales Miss

Theravance (TBPH) reports a narrower-than-expected loss for the third quarter of 2022. Revenues decline year over year.

Should Vanguard Mega Cap Value ETF (MGV) Be on Your Investing Radar?

Style Box ETF report for MGV